Monte Rosa Therapeutics, Inc.

GLUE · Biological Products, (No Diagnostic Substances) · 84.5M shares · +44%/yr ↑ dilution · EDGAR filings ↗

Reference price $21.42 · est. market cap ~$1.8B — last insider sale, 2026-06-24 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)

Grade

D46

Clinical/early-stage biotech — molecular-glue-degrader clinical, well-funded.

Strengths

Liquidity — current ratio 6.1 (61st)

Risks

Pre-revenue, deep losses — per metrics
Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
Binary clinical & funding risk — per 10-K

Notable findings

Exec changeRecent 8-K item 5.02 8-K ↗
Cash burnNegative free cash flow (-27.5M)
Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
Chronic dilutionShare count +44%/yr over 3y (dilution, book value/share -71%)
Strong balance sheetStrong balance sheet — $377M cash & investments, ~55 quarters of runway
New fund positionNotable fund(s) opened this quarter: RENAISSANCE TECHNOLOGIES LLC
Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
AccumulatingInstitutional holders rose 9→10 QoQ (2025-12-31→2026-03-31)
Trial readout soonUpcoming trial readout ~2026-05 — PHASE1/PHASE2 · NSCLC
Notable holderHeld by 5 notable fund(s): STATE STREET CORP, FMR LLC, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
Insider sellingInsider selling — 29 open-market sale(s) by 7 insider(s) (cluster of 7 insiders, ~$3M, last 6mo) Form 4 ↗

Key metrics

Return on equity

-16.6%

Return on assets

-8.6%

Current ratio

6.1×

Free cash flow

-$27M

Tangible book value

$233M

Cash & investments

$377M

Cash runway

55q

Insider transactions · last 18 months

Date	Insider	Type	Shares	Price
2026-06-24	Janku Filip	Option exercise	30K	$7.56
2026-06-24	Janku Filip	Sell	30K	$21.42
2026-06-23	Townson Sharon	Option exercise	3.0K	$6.14
2026-06-23	Townson Sharon	Sell	3.0K	$20.00
2026-06-23	Champoux Jennifer	Option exercise	2.2K	$3.98
2026-06-23	Champoux Jennifer	Sell	2.2K	$20.00
2026-06-23	Janku Filip	Sell	12K	$20.22
2026-06-23	Janku Filip	Option exercise	6.0K	$7.56
2026-06-17	Champoux Jennifer	Option exercise	2.2K	$3.98
2026-06-17	Champoux Jennifer	Sell	2.2K	$19.00
2026-06-17	Townson Sharon	Option exercise	3.0K	$6.14
2026-06-17	Townson Sharon	Sell	3.0K	$19.00
2026-06-01	Warmuth Markus	Sell	468	$19.73
2026-06-01	Warmuth Markus	Sell	5.0K	$19.41
2026-05-29	Townson Sharon	Option exercise	6.0K	$6.14
2026-05-29	Townson Sharon	Sell	6.0K	$19.87
2026-05-27	Champoux Jennifer	Option exercise	2.2K	$3.98
2026-05-27	Champoux Jennifer	Sell	2.2K	$20.00
2026-05-22	Champoux Jennifer	Option exercise	2.2K	$3.98
2026-05-22	Champoux Jennifer	Sell	2.2K	$19.00
2026-05-21	Manning Anthony M.	Option exercise	10K	$4.16
2026-05-21	Manning Anthony M.	Sell	10K	$18.01
2026-05-01	Warmuth Markus	Sell	5.5K	$18.92
2026-04-14	Warmuth Markus	Sell	8.0K	$17.64
2026-04-09	Nickson Philip	Sell	5.8K	$17.69
2026-04-06	Bowen Matthew	Grant	4.3K	—
2026-03-04	Dunn Edmund	Sell	139	$17.96
2026-03-02	Warmuth Markus	Sell	5.5K	$17.92
2026-03-02	Dunn Edmund	Option exercise	536	$13.41
2026-03-02	Dunn Edmund	Sell	536	$17.50
2026-02-27	Dunn Edmund	Option exercise	25K	$13.41
2026-02-27	Dunn Edmund	Sell	25K	$18.10
2026-02-23	Janku Filip	Sell	9.2K	$19.50
2026-01-07	Warmuth Markus	Sell	3.7K	$23.24
2026-01-07	Warmuth Markus	Sell	1.4K	$23.88
2026-01-07	Warmuth Markus	Sell	309	$24.57
2026-01-05	Warmuth Markus	Sell	10K	$15.17
2026-01-05	Nickson Philip	Sell	3.2K	$15.17
2026-01-05	Champoux Jennifer	Sell	2.6K	$15.17
2026-01-05	Dunn Edmund	Sell	1.0K	$15.17
2026-01-05	Janku Filip	Sell	3.2K	$15.17
2026-01-05	Townson Sharon	Sell	3.2K	$15.17
2026-01-02	Champoux Jennifer	Grant	35K	—
2026-01-02	Janku Filip	Grant	31K	—
2026-01-02	Nickson Philip	Grant	28K	—
2026-01-02	Townson Sharon	Grant	35K	—
2026-01-02	Warmuth Markus	Grant	90K	—
2025-06-03	Dunn Edmund	Sell	2.1K	$4.45
2025-03-24	Leo Chandra P.	Buy	10K	$5.84
2025-01-02	Nickson Philip	Grant	36K	—
2025-01-02	Dunn Edmund	Grant	12K	—
2025-01-02	Warmuth Markus	Grant	128K	—
2025-01-02	Janku Filip	Grant	36K	—
2025-01-02	Champoux Jennifer	Grant	30K	—
2025-01-02	Townson Sharon	Grant	36K	—

All non-derivative Form 4 activity (SEC), newest first.

Clinical trials

Trial	Title	Phase	Status	Primary completion
NCT07119125 ↗	A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP Healthy Volunteers, Elevated CRP	PHASE1	Active Not Recruiting	2026-07-01
NCT05546268 ↗	Study of Oral MRT-2359 in Selected Cancer Patients NSCLC, SCLC	PHASE1/PHASE2	Active Not Recruiting	2026-05-01
NCT06597799 ↗	First-in-human Study of MRT-6160 in Healthy Subjects Healthy Volunteers	PHASE1	Completed	2025-04-10

Source: ClinicalTrials.gov (U.S. NIH) · active studies first.

Notable events (8-K)

Date	Items
2026-06-11	Shareholder vote	filing ↗
2026-05-07	ResultsExhibits	filing ↗
2026-03-17	ResultsExhibits	filing ↗
2026-02-10	Exec/director change	filing ↗
2026-01-09	Material agreementOtherExhibits	filing ↗
2026-01-07	Reg FDOtherExhibits	filing ↗
2026-01-07	OtherExhibits	filing ↗
2025-12-16	Reg FDOtherExhibits	filing ↗

Recent filings

Form	Filed	Period	Accession
8-K	2026-06-11	2026-06-11	0001193125-26-267465 ↗
10-Q	2026-05-07	2026-03-31	0001193125-26-210358 ↗
8-K	2026-05-07	2026-05-07	0001193125-26-210298 ↗
10-K	2026-03-17	2025-12-31	0001193125-26-109360 ↗
8-K	2026-03-17	2026-03-17	0001193125-26-109353 ↗
8-K	2026-02-10	2026-02-09	0001193125-26-044616 ↗
8-K	2026-01-09	2026-01-08	0001193125-26-009005 ↗
8-K	2026-01-07	2026-01-07	0001193125-26-006341 ↗
8-K	2026-01-07	2026-01-07	0001193125-26-005420 ↗
8-K	2025-12-16	2025-12-16	0001193125-25-319981 ↗
8-K	2025-11-06	2025-11-06	0001193125-25-268042 ↗
10-Q	2025-11-06	2025-09-30	0001193125-25-268045 ↗